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A B S T R A C T
Background: Insomnia is increasingly recognized to be comorbid with one or more medical conditions.
This study used an online research platform to characterize insomnia across different mental and phys-
ical conditions.
Methods: A custom cross-sectional survey was ﬁelded online to 31,208 users of the patient community
PatientsLikeMe. The survey queried members on National Sleep Foundation-deﬁned insomnia risk (waking
up feeling unrefreshed, diﬃculty falling asleep, waking in the middle of the night, or waking too early).
Results: Complete results were obtained from 5256 patients with 11 comorbid conditions. Seventy-six
percent of US-based respondents were at risk for insomnia. Patients who reported diﬃculty falling asleep
were found to have nearly twice the odds of self-reporting insomnia (odds ratio [OR]: 1.84; 95% conﬁ-
dence interval [CI]: 1.5–2.1) when compared to those who do not have diﬃculty falling asleep, whereas
those who reported waking during the night or waking up unrefreshed were no more likely (OR: 1.025 and
1.032, respectively) to report that they suffered from insomnia than those who did not experience these
issues. Although insomnia was self-reported as severe or very severe across most conditions, few re-
spondents had actually been diagnosed with insomnia by a physician. After adjustment for age and gender,
there was an independent and strong effect of primary condition severity on insomnia risk, and those
with severe epilepsy (0.93), depressive disorders (0.92), and ﬁbromyalgia (0.92) occupied the highest risk
probabilities.
Conclusions: The high rate of severity and frequency of insomnia across a multitude of mental and phys-
ical conditions reveals an opportunity for better disease management through enhanced insomnia
awareness.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Chronic insomnia is an under-researched public health crisis
affecting 10–20% of the United States (US) general population and
costs billions of dollars annually [1,2]. The recent International Clas-
siﬁcation of Sleep Disorders Version 3 (ICSD-3; 2014) deﬁnes
insomnia as, “a persistent diﬃculty with sleep initiation, duration,
consolidation or quality that occurs despite adequate sleep oppor-
tunity, and associated daytime impairment.” [3] The National Sleep
Foundation (NSF) describes ﬁve types of insomnia: acute, chronic,
comorbid, onset, andmaintenance insomnia [4]. However, the diverse
nature of the symptoms and causes of insomnia, as well as the wide
range of physical and mental disorders that often precipitate in-
somnia, have made it diﬃcult to develop a consensus on the
deﬁnition of insomnia, limiting the ability to identify affected
populations.
Sleep disturbances, particularly insomnia, are increasingly
recognized to be comorbid with one or more medical and neuro-
psychiatric conditions, including anxiety, depression, diabetes, and
Parkinson’s disease [2,5–12]. Individuals with insomnia are more
likely to have multiple comorbid medical conditions than those
without insomnia [5]. In addition, studies indicate that patients with
Abbreviations: NSF, National Sleep Foundation; SD, standard deviations; AOR, ad-
justed odds ratios; GLM, generalized linear ﬁxed-effects model.
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chronic medical disorders often have fewer hours of sleep and less
restorative sleep compared to healthy individuals, and this poor sleep
may worsen symptoms of their underlying disorder [6,9,13].
There are several tests which have been used historically to di-
agnose insomnia, such as sleep logs, blood tests, and sleep studies
(ie, polysomnography) [1,14], each with their strengths and limi-
tations. For example, polysomnography laboratories provide a high
level of detail, but they are limited by their artiﬁcial environment
and expense. Traditional paper sleep diaries suffer from “the parking
lot effect,” that is, patients might make several diary entries at a
single time, rather than proximal to the experience [15,16]. These
resource-intensive methods also limit the ability of researchers to
gain insight into the linkage between insomnia and comorbid con-
ditions on a large scale. The emergence of virtual registries or
“patient-powered research networks” offers new opportunities for
collecting vast quantities of patient-reported data from patients living
with chronic illness reporting from the comfort of their own homes
or even their mobile devices [17,18]. Websites that collect patient-
reported data about sleep have the potential to inform research about
the relationship between insomnia and chronic health conditions
in a way that has historically been impossible to do eﬃciently at a
large scale. Furthermore, people with sleep-related conditions are
increasingly using the Internet for education, support, and even treat-
ment recommendations [19–30].
PatientsLikeMe (PLM) is a patient-powered research networkwith
patient communities devoted to a variety of conditions, many of
them chronic (eg, amyotrophic lateral sclerosis, Parkinson’s disease,
and epilepsy). In the present study, we used the PLM research
network to gather data on the incidence and nature of insomnia in
patients already self-deﬁned in the network as having one or more
diseases/disorders. We developed and administered a cross-
sectional survey to a subset of PLMmembers in an effort to describe
the overall prevalence of insomnia in the PLM population and to
characterize the nature of insomnia experienced by PLMmembers.
Our goal was to explore several important questions: (1) What are
the rates of insomnia across an online communitywithmajor chronic
conditions? (2) How do the characteristics of insomnia vary across
different mental and physical conditions? (3) What are the contri-
butions of important demographic and disease dimensions to the
risk of insomnia?
2. Materials and methods
2.1. PatientsLikeMe
PLM has more than 300,000 members with over 2000 different
conditions. PLMmembers are regularly invited to share data about
a number of symptoms including sleep problems, thus creating a
unique opportunity to examine insomnia acrossmany serious chronic
conditions. PLM is an adaptable data collection system that col-
lects a range of health data directly from patients, including condition
history, speciﬁc condition outcomes, symptoms, treatments, side
effects, procedures, hospitalizations, blood work, quality of life, and
unstructured free text. Upon registration, patients are asked to enter
their primary condition – or their chief reason for using the site –
and as many secondary conditions as they choose.
Data entry is supported bymedical ontologies such as theMedical
Dictionary for Regulatory Activities (MedDRA) [31], the Interna-
tional Classiﬁcation of Functioning, Disability and Health (ICF) [32],
the International Classiﬁcation of Diseases (ICD-10) [33], and by da-
tabases such as the US National Library of Medicine’s RxNorm
(RxNorm) [34]. Patient-submitted terminology is reviewed by trained
clinicians andmapped to relevant clinical terminology [35,36]. Users
are prompted to submit common personal health data at speciﬁc
time points (eg, demographics, commonly prescribed treatments,
and common symptoms) entering as little or as much information
as they like on their chosen schedule.
2.2. Custom cross-sectional sleep survey
2.2.1. Survey development
A cross-sectional survey was developed to describe inmore detail
the overall prevalence of insomnia in the PLM population, to char-
acterize the nature of insomnia experienced by patients, and to
understand how patients viewed and addressed their sleep prob-
lems. The survey (as with all data entry on the PLM platform) was
in English. A pilot survey was tested on 100 PLM users over a period
of two weeks in June 2013. Changes were made based on feed-
back from the pilot group to clarify question wording and streamline
branching patterns in the ﬁnal survey. The ﬁnal survey consisted
of 96 items within nine domains (general health, sleep problems,
NSF questions, sleep problem severity, sleep quality, help-seeking,
sleep medication use, and effectiveness and attitudes). It included
questions on general health, sleep problems, risk of insomnia, treat-
ments used, and impact of sleep problems on quality of life.
Survey responses were then matched by user identiﬁcation
number to available patient proﬁle data, which included demo-
graphic information, primary health condition, other comorbid
conditions reported, insomnia symptom reports, and typical in-
somnia severity scores. Insomnia symptom reports are obtained
when PLMmembers are invited to rate ﬁve core symptoms that are
broadly relevant to chronic conditions: (1) anxious mood, (2) de-
pressedmood, (3) fatigue, (4) insomnia, and (5) pain. Each is a single
item and is rated on a severity scale (none, mild, moderate, or severe).
A date stamp is recorded at the same time as symptom severity is
assessed and patients can add ratings over time. In this way, lon-
gitudinal insomnia symptom proﬁles are collected. Patients who
completed at least one insomnia symptom report on the platform
were matched to their survey response.
2.2.2. Estimating insomnia risk
The NSF categorizes insomnia by four primary characteristics
which include (1) waking up feeling unrefreshed, (2) diﬃculty falling
asleep, (3) waking in the middle of the night, or (4) waking too early
[4]. These insomnia characteristics can occur independently or jointly.
To estimate each respondent’s risk of insomnia, participants were
asked a series of questions about their sleep problems in the past
12 months. This included the four NSF characteristics of insomnia
and the frequency with which patients experience them (every night/
almost every night, a few nights a week, a few nights a month, rarely,
or never). In addition, participants were asked to what extent their
sleep problem had an impact on their daily activities (not at all, a
little, some, a lot, extremely). Those who reported that their problem
occurred at least a few nights a week and that it affected their daily
activities (a lot or extremely) were classiﬁed as being at risk for in-
somnia, according to the NSF deﬁnition [37].
Four distinct sleep subtypes were based on the four NSF char-
acteristics of insomnia described earlier. To possess any sleep
subtype, respondents reported any characteristic based on frequen-
cy and impact, per the NSF deﬁnition. Respondents could identify
themselves as having more than one NSF sleep subtype. In addi-
tion to the NSF deﬁnition of insomnia, survey participants were also
asked if they thought they had a sleep problem (yes, no, not sure).
Those responding yes or not sure were asked about the extent to
which their sleep problems were because of insomnia versus some
other condition or reason (including sleep apnea, restless leg syn-
drome (RLS), depression stress/anxiety, teeth grinding, and worry).
Respondents could answer that their sleep problems were due to
insomnia by varying degrees of not at all, a little, some, a lot, or ex-
tremely. This measure was further dichotomized before analyses,
where those responding some, a lot, or extremely were those who
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self-reported they had insomnia versus those who did not (i.e., those
who responded not at all or a little). Respondents were also asked
if they had been diagnosed with insomnia (yes/no).
Participants stating that they had or were unsure if they had a
sleep problem were asked to rate the severity of their problem as
none (0), mild (1), moderate (2), severe (3), or very severe (4). Re-
spondents were also asked to rate the severity of their main health
problem in the past 12 months, with response options ranging from
none (0), mild (1), moderate (2), severe (3), to very severe (4). Before
multivariable modeling, primary condition severity was classiﬁed
into three categories: (1) mild (included none and mild), (2) mod-
erate, and (3) severe (included severe and very severe).
For all longitudinal insomnia symptom data, typical insomnia se-
verity was deﬁned as the most commonly reported symptom value
across multiple insomnia symptom reports per respondent, de-
faulting to the less severe category in the case of ties.
2.2.3. Survey inclusion criteria
The inclusion criteria for the survey were members of PLM who
had been active on the site (ie, had logged in) within the last 90
days before the launch of the survey, and who were >18 years of
age. Those who were invited to take the survey were sent a private
message on the website that described the purpose of the re-
search. This message required that potential participants click on
a button either to participate in or to opt out of the study. Those
who opted out were not sent further messages regarding partici-
pation in the study. Those who did not open the message, or who
did not select to participate in or to opt out of the survey, were sent
a simple remindermessage. Thosewho chose to continuewere taken
to the survey start page. The survey was ﬁelded online from July
15, 2013 to July 30, 2013 to 31,208 users of the PLM website.
2.3. Statistical analyses
Average disease durationwas calculated as the difference between
the date of survey close (July 31, 2013) and the patient’s ﬁrst re-
ported symptom of their primary condition (reported retrospectively,
in many cases) in years. Key demographic variables, such as gender
and age, were also matched from proﬁle data to survey responses.
As a preface to the main analyses, survey respondents were com-
pared to non-respondents on various demographic characteristics
to detect any potential response biases. Descriptive statistics were
used to describe the distribution of survey variables and mea-
sures, and the rates of insomnia across chronic conditions.
Frequencies (n) and percent (%) were used for categorical vari-
ables, andmeans and standard deviations (SD) were used to describe
central tendency for continuous variables. Contingency table
methods, such as chi-square statistics, were used to test bivariate
associations between categorical variables, such as the proportion
diagnosed at each sleep problem severity level, and Fisher’s exact
testing was used when appropriate.
Univariable and multivariable logistic regression modeling was
used to evaluate dichotomous outcomes of interest such as self-
reporting insomnia (yes/no) on the basis of whether or not patients
had various NSF sleep subtype predictors. Basic sensitivity analy-
ses were conducted on ordinal outcome variables, such as self-
reported insomnia, before dichotomization in order to deﬁne the
cut-point that would ensure homogeneity within strata and het-
erogeneity between them.
Prior to model building, age was entered into the model as both
a continuous and ordinally scored variable in order to deﬁne the
most feasible binary split. Those aged 60 years and older experi-
enced a differential risk of NSF-deﬁned insomnia risk comparedwith
those younger than 60 years. The ﬁnal age variable categorization
was conﬁrmed with the likelihood ratio test.
To predict the presence of insomnia risk based on demograph-
ic, clinical, and condition-associated factors, a series of three
multivariable logistic regression models were run, and a sequen-
tial approach was used for entry of predictors into each model. A
base model consisting of only demographic characteristics was ini-
tially run; primary condition severity was entered into the next
model, and the ﬁnal model included primary condition type and
severity. Variables were entered sequentially across the models in
order to ascertain any added effect given stronger predictors already
in the model, and to ascertain any changes in the effect estimates
for existing covariates. Because it was hypothesized that the type
and severity of one’s primary condition would have a heteroge-
neous effect on NSF-deﬁned insomnia risk (and to better discern
the individual effects of primary condition at each severity level),
a condition/severity interaction term was added to the ﬁnal model.
Logistic regression models reported adjusted odds ratios (AOR), cor-
responding conﬁdence intervals, and an estimate of model ﬁt (as
quantiﬁed by the c-statistic) [38].
The ﬁnal model was ﬁt as both a logistic regression and gener-
alized linear ﬁxed-effects model (GLM) with the logit link function
using the GLIMMIX procedure. This allowed for the modeling of in-
dividual predicted probabilities of insomnia for each primary
condition type and at each condition/severity level while control-
ling for other model covariates. The ﬁnal model used the entire
population of survey responses (including incomplete surveys) in
order to increase applicable disease count totals, particularly for
primary conditions where cell counts were small. Post-hoc sensi-
tivity analyses among survey completers were conducted in order
to observe any changes in effect estimates. P-values ≤0.05 were con-
sidered statistically signiﬁcant, and all tests were two-tailed. Analyses
were performed in SAS Version 9.4 (Statistical Analysis Software,
Cary, NC, USA).
3. Results
3.1. Survey participants
At the time of the survey’s administration, a total of 63,028 PLM
members had completed an insomnia symptom report at least once.
The survey was administered to 31,208 users who had logged onto
PLM website at least once in the preceding 90 days. A total of 513
invited patients deactivated their user accounts during the course
of the survey ﬁelding period, such that 30,695 members contrib-
uted analyzable invitations (Supplementary Fig. S1). Of those who
opened the emailed invite, 1765 opted out, 6457 went on to par-
ticipate in the survey (45.7% participation rate), and 5256 completed
the survey in its entirety (37.3% completion rate). An analysis of
survey respondents (n = 6457) and non-respondents (n = 22,473) in-
dicated that, on average, respondents were slightly older than non-
respondents (mean: 50.3; SD 12.8 vs. 46.9; SD: 13.9; p < 0.05), but
the distribution of gender and the frequency of most primary con-
ditions were comparable between groups. However, compared to
non-respondents, respondents more often reported multiple scle-
rosis (15.1% vs. 10.4%; p < 0.01) or Parkinson’s disease (6.8% vs. 3.4%;
p < 0.01), and less often reported type 2 diabetes (7.7% vs. 11.0%;
p < 0.01) as their primary condition.
3.2. Primary conditions of survey completers
Table 1 outlines the demographic and clinical characteristics of
the 5256 survey completers, subdivided by primary condition. Survey
completers were predominantly female (69.5%), on average 50 years
old, more than half were from the US (62.5%), and the majority had
completed at least some college (80.2%). Condition-speciﬁc results
suggest the gender distribution of PLM by primary condition had
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a higher female proportion and reported a higher educational level
relative to the wider population.
The largest group of respondents were patients with primary
ﬁbromyalgia (n = 869, 16.5%) followed bymultiple sclerosis (n = 802,
15.3%), type 2 diabetes (n = 405, 7.7%), and Parkinson’s disease
(n = 356, 6.8%) (Table 1). The next most frequently reported primary
conditions included amyotrophic lateral sclerosis, bipolar disor-
der (I and II), Crohn’s disease, depression (includingmild depression,
major depressive disorder, and post-traumatic stress disorder), ep-
ilepsy, idiopathic pulmonary ﬁbrosis, and rheumatoid arthritis. This
made up nearly 68% of the total sample of survey completers. The
average primary condition disease duration among the sample was
15.3 years, where epilepsy had the longest duration with 26 years,
and those with idiopathic pulmonary ﬁbrosis had the shortest time
since ﬁrst symptom, averaging four years.
3.3. Rates of insomnia across conditions
Compared to 9% of the general US population [39], 78% of US-
based PLM respondents who completed the entire survey were at
risk for insomnia according to the NSF deﬁnition, meaning that 78%
experienced at least one sleep issue regularly in terms of frequen-
cy and impact, and in all cases, the PLMUS population reported each
sleep issue at a twofold higher level than the general US popula-
tion as reported by the NSF (Fig. 1A). In addition, 44% of PLM
respondents reported awakening during the night and 42% re-
ported awakening unrefreshed every night or almost every night.
While the larger PLM cohort (~63% U.S.) had a higher female pro-
portion than the general US population as assessed by the NSF cohort
(69.6% vs. 51%), the two samples were similar in terms of age (50.6
years vs. 49 years) and racial makeup (88.5% white vs. 84% white)
[39]. It should be noted that the NSF aimed to sample equal numbers
of men and women, so it is unknown how much more female the
PLM population is compared to the general US population experi-
encing sleep problems.
For the participants who completed the survey, more than 50%
patients were at risk for insomnia for each primary condition ex-
amined. Insomnia risk according to the NSF deﬁnition was highest
for those with ﬁbromyalgia (91.5%), Crohn’s disease (87.5%), de-
pressive disorders (85.4%), and rheumatoid arthritis (85.0%) (Fig. 1B).
For all survey completers who reported a primary condition, we
further analyzed whether or not the respondent reported being for-
mally diagnosed with insomnia by a physician, whether they were
undiagnosed, or whether they were unsure for each primary con-
dition (Fig. 2). Across each primary condition, the vast majority of
respondents reported not being diagnosed with insomnia by a phy-
sician, although in every case, more than half of those within any
speciﬁc primary condition were at risk for insomnia according to
NSF criteria. The largest proportion of undiagnosed insomnia was
96.2% for those who reported amyotrophic lateral sclerosis as their
primary condition, and the lowest proportion was 60% for those with
depressive disorders.
3.4. Characteristics of insomnia across conditions, by severity and
diagnosis
Across most conditions, a patient-reported insomnia diagnosis
was signiﬁcantly associated with the most severe insomnia sever-
ity scores (Fig. 3). Diagnostic rates, however, even among those with
the most severe insomnia scores over time, were not very high. Only
37.0% of those reporting severe insomnia among ﬁbromyalgia pa-
tients reported being diagnosed with insomnia by a physician, and
only 42.9% of those reporting severe insomnia among those with
depressive disorders had been diagnosed formally (Fig. 3). For most
conditions, except for epilepsy and idiopathic pulmonary ﬁbro-
sis, < 50% of those with severe insomnia reported being diagnosed
with insomnia by a health-care provider. For rheumatoid arthritis
and type 2 diabetes, < 20% of those with typically severe insomnia
(18.2% and 11.7%, respectively) were formally diagnosed.
Although diagnostic rates among those with moderate typical
insomnia generally were similar to diagnostic rates among the most
severe, in many cases they were substantially lower (amyotrophic
lateral sclerosis, epilepsy, ﬁbromyalgia, multiple sclerosis, and Par-
kinson’s disease), and in some cases they were higher (bipolar
disorder, rheumatoid arthritis, and type 2 diabetes). This may in-
dicate that at least for some conditions, severe insomnia is expected,
and it may be considered a by-product or symptom of the condi-
tion itself, rather than an independent issue warranting formal
diagnosis.
3.5. Characteristics of insomnia across conditions, by NSF criteria
As respondents could experience one or more sleep issues si-
multaneously, the burden of sleep disruption was calculated among
the total sample as well as by primary condition. Overall, 33.1%
(n = 1742) of the population had all four sleep issues (or all four NSF
subtypes, i.e., waking up feeling unrefreshed, diﬃculty falling asleep,
waking in the middle of the night, and waking too early), 22.0%
(n = 1158) had one, 13.8% (n = 727) had two, and 8.1% (n = 427) had
three. Across conditions, the heaviest insomnia burden with the
Table 1
Demographic data of PatientsLikeMe survey completers by primary condition.
Total Fibromyalgia Multiple
sclerosis
Type 2
diabetes
Parkinson’s
disease
Epilepsy Depressive
disorders
ALS Bipolar
disorder
Rheumatoid
arthritis
Crohn’s
disease
IPF
n (% of total) 5256 (100) 869 (16.5) 802 (15.3) 405 (7.7) 356 (6.8) 266 (5.1) 185 (3.5) 185 (3.5) 184 (3.5) 167 (3.2) 80 (1.5) 71 (1.4)
Female, % 69.6 92.4 77.5 51.1 51.4 59.4 68.6 42.7 70.6 89.8 77.5 45.1
Age in years,
mean (SD)
50.6 (12.5) 49.8 (10.5) 49.8 (10.3) 55.8 (10.1) 62.8 (8.8) 45.4 (12.7) 46.4 (12.0) 57.7 (9.6) 43.0 (11.9) 50.3 (11.1) 43.3 (12.3) 65.0 (8.2)
Race, % white 88.5 91.4 90.5 74.3 93.8 88.7 87.5 94.6 86.9 87.4 97.5 94.3
United
States, %b
62.5 61.5 75.9 26.2 76.1 80.8 56.8 65.4 60.9 58.1 35.0 66.2
Educational
Level:
Some college
or more, %
80.2 78.8 82.4 72.4 88.6 82.1 79.8 88.9 79.8 80.1 68.0 74.6
Disease
duration, y
Mean (SD)a
15.3 (12.6) 15.4 (11.4) 15.7 (10.6) 10.7 (8.6) 9.3 (6.8) 26.5 (15.6) 21.5 (14.0) 6.2 (5.7) 22.7 (13.7) 13.4 (11.5) 21.1 (12.8) 4.3 (3.8)
Abbreviations: Fibro., ﬁbromyalgia; ALS, amyotrophic lateral sclerosis; IPF, idiothic pulmonary ﬁbrosis.
a n = 3965 with analyzable data for disease duration.
b Approximately 90% of survey completers were either from the US (62.5%), United Kingdom (12.8%), Canada (8.8%), or Australia (3.8%).
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highest proportion of respondents reporting experiencing all four
types of sleep issue were borne by patients with ﬁbromyalgia (61.1%),
depressive disorders (42.2%), bipolar disorders (42.4%), Crohn’s
disease (38.8%), and rheumatoid arthritis (38.3%) (Fig. 4).
An assessment of the frequency of each sleep subtype was con-
ducted among the survey participants, and by primary condition.
Condition-speciﬁc results showed much the same trend as ob-
served with the overall sample population. That is, of the four NSF-
deﬁned sleep subtypes, themost commonly reported subtypes across
the 11 primary conditions were waking up unrefreshed and waking
during the night (Supplementary Fig. S2). Diﬃculty falling asleep was
the least common subtype for every condition except depressive
disorders and bipolar disorder.
Equally important was the patients’ interpretation of the burden/
prevalence of their insomnia. When self-reported insomnia was
regressed against the four sleep subtypes, patients who reported
diﬃculty falling asleep were found to have nearly twice the odds of
self-reporting insomnia (OR: 1.84; 95% CI: 1.5–2.1) when com-
pared to those who do not have diﬃculty falling asleep (Fig. 5), after
adjusting for any one of the other three subtypes. Patients who re-
ported waking during the night or waking up unrefreshed were no
more likely (OR: 1.025 and 1.032, respectively) to report that they
suffered from insomnia than those who did not experience these
sleep issues, even after controlling for other subtypes (eg, diﬃcul-
ty falling asleep and waking up too early).
3.6. Contribution of demographic and disease dimensions to NSF-
deﬁned insomnia risk
The results for the series of models are presented in Table 2. As
is seen in the unadjusted demographic model (Model 1), female
gender and increasing age were signiﬁcant predictors of insomnia
risk. Speciﬁcally, females had 1.67 times the odds (ie, 67% higher
risk) for insomnia compared to males (AOR: 1.67; 95% CI: 1.45, 1.91),
while those aged 60 years or older had only 0.57 times the odds
(or were 43% less likely) to be at risk for insomnia when com-
pared to those younger than 60 years of age (AOR: 0.57; 95% CI: 0.50,
0.66).
When controlling for primary condition severity (Model 2), female
gender and older age became less important predictors of insom-
nia risk (female gender OR: 1.45; older age OR: 0.59), while for every
one unit increase in primary condition severity (none to mild, mild
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Fig. 1. A) Patients at risk of insomnia in the general US adult population (NSF) compared to US-based PatientsLikeMe survey completers with other chronic conditions;
B) Percent of PatientsLikeMe survey completers at risk for insomnia, by primary condition. Abbreviations: PLM, PatientsLikeMe survey completers; NSF, general US adult
population according to National Sleep Foundation.
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to moderate, moderate to severe, or severe to extremely severe) in-
somnia risk increased by 78% (AOR: 1.78; 95% CI: 1.65, 1.93). In
addition, Model 2 outperforms Model 1 with regard to classiﬁca-
tion of insomnia risk (c-statistic = 0.67 vs. 0.59).
In the full and ﬁnal model (Model 3), demographic covariates,
severity, primary condition type, and the interaction between
primary condition type and severity were included. Severe or ex-
tremely severe levels of epilepsy, depressive disorders, and
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ﬁbromyalgia had the highest predicted probability of insomnia risk,
controlling for age and gender (93% (0.81–0.97); 92% (0.83–0.96);
and 92% (0.89–0.94), respectively), while amyotrophic lateral scle-
rosis at all severity levels had the lowest predicted probability of
insomnia risk (Table 2).
It is important to note that across all conditions, the probabil-
ity of being at risk for insomnia was at least 50%, even at the mildest
severity levels of primary condition. Upon adjustment for clinical
factors such as condition and severity, the effects of female gender
and older age diminished signiﬁcantly as shown by adjusted OR es-
timates [AOR (female) = 1.14, AOR (≥60 years) = 0.61], and the full
model was also the best-ﬁtting, with a c-statistic of 0.71 (Table 2).
The patterns of insomnia risk across severity levels varied by
primary condition. For some chronic conditions (including multi-
ple sclerosis and type 2 diabetes), the risk of insomnia increased
uniformly at each level of primary disease severity, while for other
conditions, such as idiopathic pulmonary ﬁbrosis and rheumatoid
arthritis, insomnia risk was less strongly inﬂuenced by increasing
primary disease severity.
The ﬁnal model was rerun post-hoc among survey completers
only (data not shown). Effect estimates did not change signiﬁ-
cantly, except for Crohn’s disease, where insomnia risk was elevated
across every severity level. Corresponding error bars were wide,
however, due to the small number of primary Crohn’s patients overall
(n = 80), and at mild and severe severity levels particularly.
Overall, model results found that the predicted probability of in-
somnia risk was uniformly high among those with comorbid
disorders, and those with epilepsy, depressive disorders and
ﬁbromyalgia seem to have the highest predicted probability of in-
somnia at most severity levels. Even after adjustment for age and
gender, there is an independent and strong effect of primary con-
dition severity on insomnia risk.
4. Discussion
The results of this study suggest that sleep issues are muchmore
prevalent across chronic diseases than have been broadly under-
stood. We found that most patients in a comorbid population were
at risk for insomnia, and experience substantial sleep disruption.
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For eight of the 11 primary conditions studied, more than 20% of
patients experienced all four types of sleep issue as deﬁned by the
NSF. Despite this, there remained gaps in diagnosis and recogni-
tion of the sleep disorder. Comparatively few of the patients in our
study reported being diagnosed with insomnia by a physician, even
among those at the highest sleep problem severity levels. We also
found patients were comparatively unlikely to self-report having
insomnia when they experience middle of the night waking, as
opposed to other types of sleep issues.
When wemodeled the contribution of demographic and disease
dimensions to NSF-deﬁned insomnia risk, severe epilepsy,
ﬁbromyalgia, and depressive disorders had the highest predicted
probabilities of insomnia risk (0.93, 0.92, and 0.92, respectively), even
after controlling for strong demographic predictors such as gender
and age. This is reﬂective of the literature, which has found strong
correlates of sleep disturbance to pain, psychosomatic and anxiety
disorders, and seizure frequency in epileptic disorders [2,5–12]. In
a post-hoc analysis, we also found insomnia risk was elevated across
every severity level for Crohn’s disease, although it should be noted
the corresponding error bars were wide. These data are in line with
a population-based study which showed that fatigue and poor sleep
are highly prevalent in active Crohn’s disease and of signiﬁcant con-
cerns for many with inactive disease [40].
Similar to other studies, female gender was found to increase
the odds of insomnia risk [41–45]. We also found older age (≥60
years) decreased the risk of insomnia. A 2003 NSF survey “Sleep in
America” found that among older adults with comorbid condi-
tions, sleep complaints were often secondary to their comorbidities,
and not to aging per se [14]. In another study which examined
the association between chronic conditions and self-reported
Table 2
Modeling the contribution of demographic and disease dimensions to NSF-deﬁned insomnia risk.
Model 1a Model 2a Model 3a
OR 95% CI OR 95% CI OR 95% CI Predicted probability Mean (lower, upper) p-value
Covariate
Female (yes) 1.67 1.45,1.91 1.45 1.26, 1.67 1.14 (0.96, 1.35) – – 0.12
Age ≥ 60 years 0.57 0.50, 0.66 0.59 0.51, 0.68 0.61 (0.51, 0.73) – – <0.001
Condition severity – – 1.78 1.65, 1.93 – – – – <0.001
Condition type – – – – – – – – <0.001
Condition severity – – – – – – – – 0.42
ALS
Mild – – – – – – 0.43 0.27, 0.60 –
Moderate – – – – – – 0.58 0.48, 0.67 –
Severe – – – – – – 0.61 0.49, 0.70 –
Bipolar disorder
Mild – – – – – – 0.57 0.41, 0.70 –
Moderate – – – – – – 0.83 0.72, 0.89 0.24
Severe – – – – – – 0.84 0.75, 0.90 0.23
Crohn’s disease
Mild – – – – – – 0.59 0.36, 0.79 –
Moderate – – – – – – 0.86 0.73, 0.93 0.24
Severe – – – – – – 0.89 0.70, 0.96 0.26
Depressive disorder
Mild – – – – – – 0.61 0.43, 0.76 –
Moderate – – – – – – 0.79 0.69, 0.85 0.68
Severe – – – – – – 0.92 0.83, 0.96 0.06
Epilepsy
Mild – – – – – – 0.62 0.52, 0.70 –
Moderate – – – – – – 0.74 0.66, 0.81 NE
Severe – – – – – – 0.93 0.81, 0.97 0.05
Fibromyalgia
Mild – – – – – – 0.80 0.60, 0.91 –
Moderate – – – – – – 0.87 0.83, 0.90 0.35
Severe – – – – – – 0.92 0.89, 0.93 0.30
IPF
Mild – – – – – – 0.73 0.52, 0.87 –
Moderate – – – – – – 0.72 0.58, 0.82 0.35
Severe – – – – – – 0.71 0.49, 0.86 0.30
Multiple sclerosis
Mild – – – – – – 0.58 0.51, 0.63 –
Moderate – – – – – – 0.73 0.68, 0.76 0.85
Severe – – – – – – 0.84 0.77, 0.88 0.19
Parkinson’s disease
Mild – – – – – – 0.65 0.55, 0.73 –
Moderate – – – – – – 0.76 0.69, 0.80 0.88
Severe – – – – – – 0.82 0.79, 0.90 0.67
Rheumatoid arthritis
Mild – – – – – – 0.69 0.43, 0.86 –
Moderate – – – – – – 0.82 0.72, 0.88 0.86
Severe – – – – – – 0.79 0.68, 0.86 0.77
Type 2 diabetes
Mild – – – – – – 0.59 0.50, 0.66 –
Moderate – – – – – – 0.73 0.67, 0.78 0.87
Severe – – – – – – 0.86 0.77, 0.91 0.15
Abbreviations: ALS, amyotrophic lateral sclerosis; IPF, idiopathic pulmonary ﬁbrosis; NE, Not estimable.
a The corresponding c-statistics were 0.59, 0.67, and 0.71 for Model 1, 2, and 3, respectively.
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severe/extreme sleep problems in adults >50 years of age [12], the
authors found a linear relationship between the number of chronic
conditions and sleep problems, and suggested that identifying co-
existing sleep problems among patients with chronic conditions and
treating them simultaneously may lead to better treatment out-
comes. The observed protective effect of older age in our study could
be due to the fact that older individuals may be less likely to report
that their sleep problems affect their lives a lot or extremely, per the
NSF deﬁnition.
This study has several limitations. While the main outcome was
the NSF deﬁnition of insomnia, patients self-reporting on the fre-
quency and impact of their sleep problemsmay or may not correlate
closely with the clinical deﬁnition of insomnia. The comorbid context
of this population complicates direct condition-by-condition com-
parisons of insomnia risk, as individuals with the primary condition
of interest may also have any number of listed conditions as sec-
ondary illnesses [46–51]. Similarly, the current activity or worsening
of one’s primary condition was not controlled for in our analyses
of insomnia diagnoses and typical insomnia severity.
Our analyses also did not control or otherwise remove individu-
als who reported sleep-related comorbidities other than insomnia,
such as restless leg syndrome (RLS) or obstructive sleep apnea (OSA).
It should be noted, however, that removing individuals with sleep-
related comorbidities from this type of comorbid population
decreases the effective sample size and makes insomnia risk esti-
mates diﬃcult to obtain, particularly for the less prevalent conditions
studied. Furthermore, the use of prescription or over-the-counter
(OTC) medications and other drugs (eg, caffeine) which can poten-
tially worsen sleep symptoms or elevate the self-reported prevalence
of the sleep subtypes mentioned here were also not controlled for
when examining the association between primary conditions and
insomnia risk. In addition, the effect estimates for certain primary
conditions such as Crohn’s disease and idiopathic pulmonary ﬁ-
brosis are already likely unstable because of small numbers of
patients comprising each condition group, which were then further
stratiﬁed by three severity levels.
Another limitation is that the PLM database does not provide
equal exposure to all diseases and some, such as amyotrophic lateral
sclerosis, may be overrepresented, whereas other common dis-
eases, such as cancer, are likely to be underrepresented. The PLM
population may not be generalizable to the insomnia patient pop-
ulation as a whole, who may or may not present with as many co-
prevalent illnesses. Indeed, the PLM population, in general and across
the conditions studied here, is skewed towards a more female, edu-
cated and engaged group of patients, which reﬂects the patient
population that regularly uses health-based Internet sites [52,53].
The presence of co-prevalent illness or symptoms is common among
real-world patient survey studies as opposed to randomized con-
trolled trials which strive to achieve balanced (and otherwise healthy)
patient groups for comparison. It is arguable whether clinical trials
are entirely reﬂective of the general population of sleep problem
sufferers as well.
Despite these limitations, this is one of the largest survey-
based studies of sleep disruption and insomnia symptoms [39,54,55].
The emergence of online patient-powered research platforms holds
great promise for certain forms of clinical research by providing rapid
access to data from large numbers of patients at frequent inter-
vals, particularly for common disorders such as insomnia. Capturing
the “patient voice” for how they perceive their insomnia should foster
amore common understanding between clinician and patient. Online
patient registries may also inﬂuence the design of clinical studies
to more directly address the most prevalent/resistant sleep issues
experienced by a certain populations. Large-scale clinical trials are
done at great expense and virtual registries can play a substitu-
tive role with increasing meaningfulness and signiﬁcance. Such
information could lead to more accurate descriptions of the
prevalence of insomnia, its progression and remission through time,
the risk factors that maintain insomnia over time, as well as
treatment strategies that work, or do not work, in given patient popu-
lations with the same comorbid conditions.
On a clinical level, these data suggest that physicians or re-
searchers treating patients with chronicmedical conditionsmaywant
to consider asking the patient about sleep at different stages, rather
than using the term “insomnia” alone. A patient’s interpretation of
the burden/prevalence of their insomnia in our study shows that
those who wake during the night or wake up unrefreshed were no
more likely to report that they suffer from insomnia than those who
did not experience these sleep issues, potentially leading to under-
diagnoses. The observed high level of insomnia and correlation with
other illness in our study suggest the need for clinicians to develop
disease-speciﬁc strategies for managing insomnia in the context of
complex comorbidities. There is a need to have better ways of clin-
ically assessing the drivers of insomnia to understand which
treatments work and the context for successful (or not successful)
treatment. There is also a need for a greater understanding of the
qualitative experience of insomnia by condition. Given sleep is such
an important issue for health and well-being, especially in indi-
viduals suffering from a comorbid condition(s), future work should
focus on enabling more effective patient/physician communica-
tion and stratiﬁcation to understand the various methods for
identifying and addressing sleep issues.
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